Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Flaherty

Showing results (281-290 of 580) with videos related to

Pageof 58
Sort By:
Circulation|April 1, 1989
Clot-selective coronary thrombolysis with pro-urokinaseJ Loscalzo, T P Wharton, J M Kirshenbaum, et al.
The Lancet. Oncology|November 20, 2016
Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trialsGeorgina V Long, Jean-Jacques Grob, Paul Nathan, et al.
Journal of the American College of Cardiology|December 1, 1984
Immediate improvement of dysfunctional myocardial segments after coronary revascularization: detection by intraoperative transesophageal echocardiographyE J Topol, J L Weiss, P A Guzman, et al.
The American Journal of Cardiology|December 15, 1991
Clot-selective coronary thrombolysis with low-dose synergistic combinations of single-chain urokinase-type plasminogen activator and recombinant tissue-type plasminogen activator. The Pro-Urokinase for Myocardial Infarction Study GroupJ M Kirshenbaum, R D Bahr, J T Flaherty, et al.
Nature Reviews. Drug Discovery|September 7, 2013
Considerations for the successful co-development of targeted cancer therapies and companion diagnosticsJane Fridlyand, Richard M Simon, Jessica C Walrath, et al.
Circulation|May 1, 1994
Recombinant human superoxide dismutase (h-SOD) fails to improve recovery of ventricular function in patients undergoing coronary angioplasty for acute myocardial infarctionJ T Flaherty, B Pitt, J W Gruber, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 23, 2025
Facts and Hopes: Toward the Next Quantum Leap in MelanomaKeith T Flaherty, Andrew E Aplin, Michael A Davies, et al.
Journal of the American Academy of Dermatology|August 21, 2016
Ki-67, p53, and p16 expression, and G691S RET polymorphism in desmoplastic melanoma (DM): A clinicopathologic analysis of predictors of outcomeNicholas F Lawrence, Marc R Hammond, Dennie T Frederick, et al.
Cancer Chemotherapy and Pharmacology|January 15, 2004
Phase I trial of the antifolate ZD9331 in combination with cisplatin in patients with refractory solid malignanciesJoshua H Bilenker, James P Stevenson, Keith T Flaherty, et al.
The Journal of Investigative Dermatology|March 20, 2015
MITF Modulates Therapeutic Resistance through EGFR SignalingZhenyu Ji, Yiyin Erin Chen, Raj Kumar, et al.
Pageof 58

Showing results (281-290 of 580) with videos related to

Sort By:
Pageof 58
Circulation|April 1, 1989
Clot-selective coronary thrombolysis with pro-urokinaseJ Loscalzo, T P Wharton, J M Kirshenbaum, et al.
The Lancet. Oncology|November 20, 2016
Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trialsGeorgina V Long, Jean-Jacques Grob, Paul Nathan, et al.
Journal of the American College of Cardiology|December 1, 1984
Immediate improvement of dysfunctional myocardial segments after coronary revascularization: detection by intraoperative transesophageal echocardiographyE J Topol, J L Weiss, P A Guzman, et al.
The American Journal of Cardiology|December 15, 1991
Clot-selective coronary thrombolysis with low-dose synergistic combinations of single-chain urokinase-type plasminogen activator and recombinant tissue-type plasminogen activator. The Pro-Urokinase for Myocardial Infarction Study GroupJ M Kirshenbaum, R D Bahr, J T Flaherty, et al.
Nature Reviews. Drug Discovery|September 7, 2013
Considerations for the successful co-development of targeted cancer therapies and companion diagnosticsJane Fridlyand, Richard M Simon, Jessica C Walrath, et al.
Circulation|May 1, 1994
Recombinant human superoxide dismutase (h-SOD) fails to improve recovery of ventricular function in patients undergoing coronary angioplasty for acute myocardial infarctionJ T Flaherty, B Pitt, J W Gruber, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 23, 2025
Facts and Hopes: Toward the Next Quantum Leap in MelanomaKeith T Flaherty, Andrew E Aplin, Michael A Davies, et al.
Journal of the American Academy of Dermatology|August 21, 2016
Ki-67, p53, and p16 expression, and G691S RET polymorphism in desmoplastic melanoma (DM): A clinicopathologic analysis of predictors of outcomeNicholas F Lawrence, Marc R Hammond, Dennie T Frederick, et al.
Cancer Chemotherapy and Pharmacology|January 15, 2004
Phase I trial of the antifolate ZD9331 in combination with cisplatin in patients with refractory solid malignanciesJoshua H Bilenker, James P Stevenson, Keith T Flaherty, et al.
The Journal of Investigative Dermatology|March 20, 2015
MITF Modulates Therapeutic Resistance through EGFR SignalingZhenyu Ji, Yiyin Erin Chen, Raj Kumar, et al.
Pageof 58